ATLAB Pharma

Nantes, France Founded: 2008 • Age: 18 yrs Acquired By Telix Pharma
Radio-antibodies for cancer treatment are developed by ATLAB Pharma.
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About ATLAB Pharma

ATLAB Pharma is a company based in Nantes (France) founded in 2008 was acquired by Telix Pharma in September 2018. ATLAB Pharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.

  • Headquarter Nantes, France
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $7.94 M (USD), Grant

    Jun 02, 2009

  • Investors
  • Employee Count
    Not available
  • Acquired by
    Telix Pharma

    (Sep 11, 2018)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of ATLAB Pharma

Investors in ATLAB Pharma

ATLAB Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Telix Pharmaceuticals.

All
Institutional
Investor Description Founded Year Domain Location
Theranostic radiopharmaceuticals are developed for cancer imaging and therapy.
Locked Locked Locked
Premium access

Investor details for ATLAB Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by ATLAB Pharma

Investments
Premium access

Investment portfolio details for ATLAB Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - ATLAB Pharma

Premium access

Detailed financials for ATLAB Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Atlab Pharma Comparisons

ATLAB Pharma Primary company
Description
Radio-antibodies for cancer treatment are developed by ATLAB...
Location
Nantes, France
Founded Year
2008
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for ATLAB Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of ATLAB Pharma

ATLAB Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Targeted and immune-oncology drugs for cancer treatment are developed.
Locked Locked Locked
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
Locked Locked Locked
Small molecules are developed for cancer and skin disease treatments.
Locked Locked Locked
Cancer therapies are developed using selective pathway inhibitors.
Premium access

Detailed competitors of ATLAB Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Atlab Pharma

Premium access

Complete news archive for ATLAB Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ATLAB Pharma

ATLAB Pharma was founded in 2008 and raised its 1st funding round 1 year after it was founded.

ATLAB Pharma is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.

ATLAB Pharma was founded in 2008 and is based in Nantes, France. Operations focus on the biotechnology sector, specifically radio immunotherapy for cancer. Monoclonal antibodies conjugated to radioisotopes are developed to deliver targeted radiation to tumor cells. The lead candidate, ATL101, targets prostate-specific membrane antigen using Lutetium-177 and has demonstrated safety and anti-tumor activity in Phase I and II trials for castrate-resistant prostate cancer.

ATLAB Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

ATLAB Pharma has 1 investor. Key investors include Telix Pharmaceuticals.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available